AXGN:NASDAQ
AxoGen, Inc Common Stock
$55.49
arrow_downward
-1.53%(-0.86) 1D
Nob 20, 10:31:57 AM GMT-5 · USD
search
Lahat ng simbolo
| Simbolo | Presyo | Palitan | % ng Pagbabago |
|---|
insights_autoBumubuo ng mga nangungunang insight para sa AXGN...
Buksan
$55.71
Mataas
$56.91
Mababa
$55.19
Mkt. cap
3.31B
Avg. na dami
1.86M
Dami
108.80K
Mataas nang 52-wk
$59.72
Mababa nang 52-wk
$25.21
EPS
-$0.65
Beta
1.21
Mga natitirang share
59.73M
Bilang ng mga empleyado
622
Buksan
$55.71
Mataas
$56.91
Mababa
$55.19
Mkt. cap
3.31B
Avg. na dami
1.86M
Dami
108.80K
Mataas nang 52-wk
$59.72
Mababa nang 52-wk
$25.21
EPS
-$0.65
Beta
1.21
Mga natitirang share
59.73M
Bilang ng mga empleyado
622
Mga balita at kwento
Mula sa mga source sa web at partner sa balita
Barron's
·
1 oras ang nakalipas
S&P 500 Skid Enters Seventh Day as Dow Nears Correction
Coinpaper
·
53 minuto ang nakalipas
S&P 500 Price Prediction: S&P 500 Falls 2.3% Below 200-Day Average
TradingView
·
46 minuto ang nakalipas
S&P 500 is on track for the worst week since the April 2025 'Liberation Day' sell-off
ChartMill
·
1 oras ang nakalipas
S&P 500 Premarket Movers Friday: Gainers and Losers
Profile
Axogen is a developer of surgical solutions, including human tissue grafts, based in Tampa, Florida. Axogen products are designed to remedy peripheral nerve damage. In 2013 the company raised $18 million in its initial public offering. Axogen uses a cell graft technology Avance to mimic a human nerve. The company also creates nerve connectors and soft tissue membranes. The company reports sensory and movement recovery in 87 percent of patients with peripheral nerve injuries. Axogen is part of the Sid Martin Biotechnology Incubator.
As of 2019, Axogen was the only commercially available nerve allograft approved by the Food and Drug Administration for clinical use. Wikipedia
Tungkol sa AxoGen, Inc Common Stock
CEO-
Mga Empleyado622
Itinatag2002
HeadquartersAlachua, Florida, Estados Unidos
SektorHealth Care
Industriya-
Websiteaxogeninc.com